Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].
Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats[1].
| Animal Model: | Sprague-Dawley rats [2] |
| Dosage: | 1, 10, and 100 mg/kg |
| Administration: | Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study) |
| Result: | Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg. |